Provided by Tiger Fintech (Singapore) Pte. Ltd.

Scienture Holdings, Inc.

1.06
+0.02001.92%
Post-market: 1.01-0.0500-4.72%19:33 EDT
Volume:99.34K
Turnover:103.91K
Market Cap:13.90M
PE:-0.38
High:1.08
Open:1.03
Low:1.00
Close:1.04
Loading ...

Scienture Appoints Co-CEOs as Suren Ajjarapu Steps Down

MT Newswires Live
·
22 May

Scienture Holdings Inc - Narasimhan Mani Appointed President and Co-CEO

THOMSON REUTERS
·
22 May

Scienture Holdings Inc - Suren Ajjarapu Steps Down as CEO and Chairman of Scienture

THOMSON REUTERS
·
22 May

Scienture Announces Executive Leadership Transition

THOMSON REUTERS
·
22 May

Scienture Holdings Inc - on May 16, Suren Ajjarapu Resigns as CEO and Chairman of Scienture Holdings - SEC Filing

THOMSON REUTERS
·
22 May

Scienture Holdings Inc - Appoints Narasimhan Mani and Shankar Hariharan as Co-Ceos - SEC Filing

THOMSON REUTERS
·
22 May

Scienture Holdings Inc. Faces Nasdaq Delisting Risk Over Minimum Bid Price Requirement

Reuters
·
22 May

Scienture announces FDA Orange Book patent listing for Arbli

TIPRANKS
·
19 May

Scienture Announces FDA Orange Book Patent Listing for Arblitm, (Losartanpotassium) Oral Suspension, 10Mg/Ml.

THOMSON REUTERS
·
19 May

BRIEF-Scienture Announces Manufacturing And Supply Chain Readiness For ArbliTM, (Losartan Potassium) Oral Suspension, 10Mg/Ml For A Target Product Launch In July 2025

Reuters
·
22 Apr

Scienture initiates supply chain activities by subsidiary to launch Arbli

TIPRANKS
·
22 Apr

SCIENTURE announces manufacturing and supply chain readiness for ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL for a target product launch in July 2025.

GlobeNewswire
·
22 Apr

Scienture Announces Manufacturing and Supply Chain Readiness for Arblitm, (Losartan Potassium) Oral Suspension, 10Mg/Ml for a Target Product Launch in July 2025.

THOMSON REUTERS
·
22 Apr

Scienture Sells 3 Subsidiaries to Tollo Health for $5 Million

MT Newswires Live
·
08 Apr

BRIEF-Scienture Announces The Divestiture Of Its Legacy Subsidiaries

Reuters
·
08 Apr

Scienture Holdings Inc - Proposed Deal for Total Consideration of $5 Mln

THOMSON REUTERS
·
08 Apr

Scienture Announces the Divestiture of Its Legacy Subsidiaries for a Total Consideration of $5 Million and Dedicates Its Full Focus to the Branded and Specialty Pharma Segment Through Scienture, Llc.

THOMSON REUTERS
·
08 Apr

SCIENTURE announces the divestiture of its legacy subsidiaries for a total consideration of $5 million and dedicates its full focus to the Branded and Specialty Pharma segment through Scienture, LLC.

GlobeNewswire
·
08 Apr

BRIEF-Scienture Holdings Files Prospectus Relates To Resale From Time To Time Of Up To 2.6 Million Shares Of Common Stock By Selling Stockholders

Reuters
·
05 Apr

Scienture files to sell 2.64M shares of common stock for holders

TIPRANKS
·
05 Apr